Rigel Pharmaceuticals Q2 EPS $(0.04) Beats $(0.08) Estimate, Sales $26.89M Beat $26.02M Estimate
Portfolio Pulse from mahesh@benzinga.com
Rigel Pharmaceuticals reported Q2 earnings per share of $(0.04), beating the analyst consensus estimate of $(0.08) by 50%. The company also reported quarterly sales of $26.89 million, beating the analyst consensus estimate of $26.02 million by 3.33%. However, this represents a 9.84% decrease in sales compared to the same period last year.
August 04, 2023 | 10:19 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Rigel Pharmaceuticals reported better than expected Q2 earnings and sales, but sales decreased compared to the same period last year.
While Rigel Pharmaceuticals beat Q2 earnings and sales estimates, the decrease in sales compared to the same period last year could potentially offset the positive impact of the earnings beat. This makes the short term price direction neutral.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100